NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $799,000, down 20 percent from $1.0 million in the second quarter of 2013.
The revenues consisted solely of product revenues from sales of the company's BGM Galectin-3 test. Product revenues were down 18 percent from $972,000 in Q2 2013.
The company reported no service revenues. It reported $34,000 in service revenues in the year-ago period.
BG also lowered its full-year 2014 guidance, noting that it no longer expects 2014 revenues to exceed 2013 revenues.